Norharman — endogenous inhibitor of morphine withdrawal

Abstract

The effects of intraperitoneally administered norharman and structurally related ibogaine have been examined on the naloxone-precipitated withdrawal syndrome in morphine-dependent rats. Norharman, similarly to ibogaine, significatly attenuated naloxone-induced withdrawal syndrome in morphine-dependent animals. Both drugs attenuated several withdrawal signs, however, norharman had a more prominent effect, reducing the withdrawal symptoms not affected by ibogaine. These results suggest that norharman, as a physiological constituence of various tissues including brain, may play an important role in the attenuation of withdrawal syndrome.

Sources

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

©2012-2019 Global Ibogaine Therapy Alliance - Privacy Policy - Contact Us

or

Log in with your credentials

or    

Forgot your details?

or

Create Account